IDiyas

For the Inventor, By the Inventor

St. Louis, France

Maurice Van Eis

USPTO Granted Patents = 13 

 

Average Co-Inventor Count = 4.2

ph-index = 4

Forward Citations = 51(Granted Patents)


Location History:

  • Buschwiller, FR (2010)
  • Basel, CH (2012)
  • St. Louis, FR (2010 - 2016)

Company Filing History:

goldMedal13 out of 3,923 
 
Novartis Ag
 patents

Years Active: 2010-2016

Loading Chart...
Loading Chart...
13 patents (USPTO):
1. 9315500 - Bicyclic heteroaryl cycloalkyldiamine derivatives (2016-04-19),
2. 9290481 - Monocyclic heteroaryl cycloalkyldiamine derivatives (2016-03-22),
3. 9029396 - Substituted indole derivatives (2015-05-12),
4. 8742132 - Indolylmaleimide derivatives processes for their production and pharmaceutical compositions (2014-06-03),
5. 8703782 - Substituted indole derivatives (2014-04-22),
6. 8426440 - Indolymaleimide derivatives (2013-04-23),
7. 8283356 - 2,4- Di(hetero)-arylamino-pyrimidine derivatives as ZAP-70 and/or SYK inhibitors (2012-10-09),
8. 8193236 - Indolylmaleimide derivatives processes for their production and pharmaceutical compositions (2012-06-05),
9. 7851475 - Substituted pyrrole-2, 5-diones as protein kinase C inhibitors (2010-12-14),
10. 7781438 - Indolylmaleimide derivatives (2010-08-24),
11. 7691861 - Indolymaleimide derivatives (2010-04-06),
12. 7671063 - 2,4 Di (hetero) -arylamino-pyrimidine derivatives as ZAP-70 and/or syk inhibitors (2010-03-02),
13. 7648989 - Indolylmaleimide derivatives as PKC inhibitors (2010-01-19),

Title: Maurice Van Eis: A Visionary Inventor in the World of Technology

Introduction:

Maurice Van Eis, a dedicated inventor based in St. Louis, France, stands as a shining example of visionary innovation, with a remarkable legacy in the realm of technology and beyond.

Latest Patents:

Van Eis boasts an impressive portfolio of 13 patents, with his latest ventures focusing on groundbreaking advancements in pharmaceuticals:

1. Bicyclic heteroaryl cycloalkyldiamine derivatives: Revolutionizing the realm of pharmaceuticals, these derivatives serve as SYK inhibitors, with immense potential for various medical applications.

2. Monocyclic heteroaryl cycloalkyldiamine derivatives: Van Eis' innovation in this field has paved the way for new pharmaceutical solutions, offering hope for improved medical treatments.

Career Highlights:

Currently affiliated with Novartis AG, a renowned pharmaceutical company, Van Eis has been instrumental in driving forward innovation and breakthroughs in the industry.

Collaborations:

Van Eis has collaborated closely with esteemed colleagues such as Jürgen Wagner and Peter Von Matt, fostering a culture of innovation and excellence within the pharmaceutical domain.

Conclusion:

In conclusion, Maurice Van Eis's relentless dedication to innovation and his groundbreaking contributions in the field of technology underscore his status as a visionary inventor. His work continues to shape the landscape of pharmaceuticals and holds promise for a brighter, healthier future.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…